Lactobacillus GG
PreclinicalSmall molecule
Lactobacillus GG is one of 24 small molecule programs targeting Pediatric. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Pediatric
#DrugCompanyPhaseTrials
1Oxycontin
PProtega
Approved
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Siliq
BBausch Health Americas, Inc.
Approved
Blincyto
AmgenPhase 3
Venclexta
AbbViePhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Fycompa
CCatalyst Biosciences
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Encephalopathy1 trial
Ulcerative Colitis1 trial
Lactobacillus GG in Pediatric Ulcerative Colitis (UC)
Withdrawn·—·Phase 2·NCT00895336
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lactobacillus GG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- VVirginia Commonwealth University